Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data

Autor: Tomida, Ryotaro, Takahashi, Masayuki, Matsushita, Yuto, Kojima, Takahiro, Yamana, Kazutoshi, Kandori, Shuya, Bando, Yukari, Nishiyama, Naotaka, Yamashita, Shimpei, Taniguchi, Hisanori, Monji, Keisuke, Ishiyama, Ryo, Tatarano, Shuichi, Masui, Kimihiko, Matsuda, Ayumu, Kaneko, Tomoyuki, Motoshima, Takanobu, Shiraishi, Yusuke, Kira, Satoru, Murashima, Takaya, Hara, Hiroaki, Matsumura, Masafumi, Kitamura, Hiroshi, Miyake, Hideaki, Furukawa, Junya
Zdroj: In Clinical Genitourinary Cancer June 2024 22(3)
Databáze: ScienceDirect
Externí odkaz: